Shanghai Haohai Biological Technology Co (SHSE:688366) Asset Turnover: 0.09 (As of Mar. 2026)


SHSE:688366 Shanghai Haohai Biological Technology Co Ltd SHSE:688366
73 GF Score
Price ¥30.65
GF Value ¥46.84
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co Asset Turnover?

Shanghai Haohai Biological Technology Co SHSE:688366 +6.17% 73 Asset Turnover is 0.09 as of Mar. 2026. GuruFocus rates SHSE:688366 with a GF Score™ of 73/100 and a GF Value™ of ¥46.84 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Shanghai Haohai Biological Technology Co's Revenue for the three months ended in Mar. 2026 was ¥571 Mil. Shanghai Haohai Biological Technology Co's Total Assets for the quarter that ended in Mar. 2026 was ¥6,693 Mil. Therefore, Shanghai Haohai Biological Technology Co's Asset Turnover for the quarter that ended in Mar. 2026 was 0.09.

Asset Turnover is linked to ROE % through Du Pont Formula. Shanghai Haohai Biological Technology Co's annualized ROE % for the quarter that ended in Mar. 2026 was 5.42%. It is also linked to ROA % through Du Pont Formula. Shanghai Haohai Biological Technology Co's annualized ROA % for the quarter that ended in Mar. 2026 was 4.40%.


Shanghai Haohai Biological Technology Co  (SHSE:688366) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Shanghai Haohai Biological Technology Co's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=294.236/5432.521
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(294.236 / 2285.74)*(2285.74 / 6693.186)*(6693.186/ 5432.521)
=Net Margin %*Asset Turnover*Equity Multiplier
=12.87 %*0.3415*1.2321
=ROA %*Equity Multiplier
=4.40 %*1.2321
=5.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Shanghai Haohai Biological Technology Co's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=294.236/6693.186
=(Net Income / Revenue)*(Revenue / Total Assets)
=(294.236 / 2285.74)*(2285.74 / 6693.186)
=Net Margin %*Asset Turnover
=12.87 %*0.3415
=4.40 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Shanghai Haohai Biological Technology Co Asset Turnover Related Terms


Shanghai Haohai Biological Technology Co Asset Turnover Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co Asset Turnover Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.30 0.38 0.38 0.35

Shanghai Haohai Biological Technology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.00 0.09 0.08 0.09

SHSE:688366 vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Haohai Biological Technology Co Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's Asset Turnover falls into.


SHSE:688366
73GF Score
Shanghai Haohai Biological Technology Co Ltd SHSE:688366
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Shanghai Haohai Biological Technology Co's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=2446.306/( (7121.392+6720.063)/ 2 )
=2446.306/6920.7275
=0.35

Shanghai Haohai Biological Technology Co's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=571.435/( (6720.063+6666.309)/ 2 )
=571.435/6693.186
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.09 mean?
Shanghai Haohai Biological Technology Co (SHSE:688366) has a Asset Turnover of 0.09 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Shanghai Haohai Biological Technology Co and its competitors.
Is Shanghai Haohai Biological Technology Co's Asset Turnover too high?
Shanghai Haohai Biological Technology Co's current Asset Turnover is 0.09. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Asset Turnover compare to VRTX and REGN?
Shanghai Haohai Biological Technology Co's Asset Turnover of 0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Shanghai Haohai Biological Technology Co and its competitors. Shanghai Haohai Biological Technology Co's current Asset Turnover is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (SHSE:688366) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥46.84, compared to a current price of ¥30.65 — trading 34.6% below its estimated fair value. The current Asset Turnover is 0.09. Shanghai Haohai Biological Technology Co's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (SHSE:688366), the current Asset Turnover is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (SHSE:688366) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of ¥30.65 is trading 34.6% below its estimated GF Value™ of ¥46.84. GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.

Key valuation signals for SHSE:688366:

  • Asset Turnover: 0.09
  • GF Value™: ¥46.84 vs. price of ¥30.65 (34.6% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688366 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 06826:Hong Kong5HB:Germany
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
73GF Score

Get the complete analysis for SHSE:688366

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥30.65
Price
¥46.84
GF Value